2017
Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service–Related Posttraumatic Stress Disorder
Byrne SP, Krystal JH, Rosenheck RA, Vessicchio J, Pietrzak RH. Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service–Related Posttraumatic Stress Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 717-721. PMID: 28945664, DOI: 10.1097/jcp.0000000000000777.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive AgentsAntipsychotic AgentsDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRandomized Controlled Trials as TopicRisperidoneSeverity of Illness IndexStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsVeteransConceptsPosttraumatic stress disorderAdjunctive risperidoneTreatment-resistant posttraumatic stress disorderClinician-Administered PTSD Scale scoresSymptom clustersStress disorderOriginal treatment regimenFirst-line pharmacotherapySpecific symptom clustersSpecific PTSD symptom clustersVeterans RANDTreatment regimenPharmacotherapeutic effectsHealth SurveyRole functioningPTSD symptom clustersTreat conditionScale scoreGreater severityVariable improvementRisperidoneTargeted pharmacotherapyPlaceboNonimprovementPharmacotherapy
2003
Treatment Models and Designs for Intervention Research During the Psychotic Prodrome
Kane JM, Krystal J, Correll CU. Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. Schizophrenia Bulletin 2003, 29: 747-756. PMID: 14989412, DOI: 10.1093/oxfordjournals.schbul.a007044.Peer-Reviewed Original ResearchConceptsPsychotic prodromePsychotic disordersEarly interventionSubsequent symptom severityTreatment modelOngoing intervention trialsSpecific symptom clustersTreatment refractorinessFunctional disabilityPatient selectionIntervention trialsFunctional outcomeProdromal symptomsDisease progressionNatural courseTarget symptomsSubsyndromal symptomsDifferent treatment modelsOutcome measuresProdromal populationTreatment responseProdromal stateTrial designSymptom clustersSymptom severity